A Vitiligo-like Cutaneous Reaction Induced by Ribociclib in Advanced Breast Cancer: An Unusual Case Report from Colombia
| dc.contributor.author | Montenegro, John Fernando | |
| dc.contributor.author | Rivas Tafurt, Giovanna Patricia | |
| dc.contributor.author | Vidal Cañas, Sinthia | |
| dc.contributor.author | Diaz Diaz, Miguel Ángel | |
| dc.contributor.author | Bermudez, Cesar Eduardo | |
| dc.contributor.author | Florez, Daniel | |
| dc.contributor.author | Bravo Gustin, Andres Felipe | |
| dc.contributor.author | Liscano, Yamil | |
| dc.date.accessioned | 2025-07-18T20:16:25Z | |
| dc.date.available | 2025-07-18T20:16:25Z | |
| dc.date.issued | 2025-05-19 | |
| dc.description | Antecedentes: Las toxicidades cutáneas asociadas a los inhibidores CDK4/6 son infrecuentes pero pueden afectar a la adherencia al tratamiento. Presentamos el caso de una paciente con cáncer de mama avanzado que desarrolló lesiones similares al vitíligo tras iniciar ribociclib, contribuyendo a la creciente evidencia de este efecto adverso poco reconocido. Métodos: Presentamos el caso de una mujer de 72 años diagnosticada en 2007 de cáncer de mama en estadio temprano, luminal A, HER2 negativo, tratada inicialmente con cirugía y tamoxifeno. En 2022 experimentó una recidiva locorregional con metástasis óseas. En enero de 2023 inició tratamiento con ribociclib más letrozol. Dos meses después presentó prurito intenso, xerosis y parestesias, seguidos de lesiones hipopigmentadas en cara y extremidades superiores. La evaluación clínica, apoyada por fotografías y una biopsia cutánea, llevó al diagnóstico de vitíligo inducido por ribociclib. El tratamiento incluyó ajustes de la dosis de ribociclib y tratamientos dermatológicos, incluidos corticosteroides tópicos, antihistamínicos y ciclos cortos de prednisona oral. Resultados: En septiembre de 2024, sus lesiones cutáneas se habían estabilizado y su prurito mejoró con una dosis reducida de ribociclib (un comprimido al día). Sin embargo, persistían las manchas hipopigmentadas, principalmente en la cara y las extremidades. A pesar de estos efectos cutáneos, mantuvo una calidad de vida aceptable y continuó con un tratamiento oncológico eficaz. | |
| dc.description.abstract | Background: Cutaneous toxicities associated with CDK4/6 inhibitors are uncommon but may affect treatment adherence. We present the case of a patient with advanced breast cancer who developed vitiligo-like lesions after initiating ribociclib, contributing to the growing evidence of this under-recognized adverse effect. Methods: We present the case of a 72-year-old woman diagnosed in 2007 with early-stage, luminal A, HER2-negative breast cancer, initially treated with surgery and tamoxifen. In 2022, she experienced locoregional recurrence with bone metastases. In January 2023, she began treatment with ribociclib plus letrozole. Two months later, she developed intense pruritus, xerosis, and paresthesia, followed by hypopigmented lesions on her face and upper extremities. Clinical evaluation, supported by photographs and a skin biopsy (led to a diagnosis of ribociclib-induced vitiligo. Management included dose adjustments to the ribociclib and dermatologic treatments, including topical corticosteroids, antihistamines, and short courses of oral prednisone. Results: By September 2024, her skin lesions had stabilized and her pruritus improved with a reduced dose of ribociclib (one tablet per day). However, the hypopigmented patches persisted, mainly on her face and extremities. Despite these cutaneous effects, she maintained an acceptable quality of life and continued effective oncologic treatment. | |
| dc.identifier.citation | Montenegro, J. F., Rivas-Tafurt, G. P., Vidal-Cañas, S., Diaz-Diaz, M. Á., Bermudez, C. E., Florez, D., Bravo-Gustin, A. F., & Liscano, Y. (2025). A Vitiligo-like Cutaneous Reaction Induced by Ribociclib in Advanced Breast Cancer: An Unusual Case Report from Colombia. Diseases, 13(5), 1–10. https://doi.org/10.3390/diseases13050158 | |
| dc.identifier.issn | 20799721 | |
| dc.identifier.uri | https://repositorio.usc.edu.co/handle/20.500.12421/7526 | |
| dc.language.iso | en | |
| dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | |
| dc.subject | autoimmune | |
| dc.subject | breast cancer | |
| dc.subject | hypopigmented | |
| dc.subject | ribociclib | |
| dc.subject | vitiligo | |
| dc.title | A Vitiligo-like Cutaneous Reaction Induced by Ribociclib in Advanced Breast Cancer: An Unusual Case Report from Colombia | |
| dc.type | Article |